Adasuve Approval History
- FDA approved: Yes (First approved December 21st, 2012)
- Brand name: Adasuve
- Generic name: loxapine
- Dosage form: Inhalation Powder
- Previous name: AZ-004
- Company: Alexza Pharmaceuticals, Inc.
- Treatment for: Agitation, Schizophrenia, Bipolar Disorder
Adasuve (loxapine) is a typical antipsychotic indicated for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.
Development History and FDA Approval Process for Adasuve
|Dec 21, 2012|| FDA Approves Adasuve (loxapine) Inhalation Powder for the Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I Disorder in Adults|
|Jul 6, 2012||Alexza Announces Adasuve (Staccato Loxapine) PDUFA Goal Date of December 21, 2012|
|May 3, 2012||Alexza Receives Complete Response Letter for Adasuve NDA|
|Jan 23, 2012||Alexza Announces Extension of the Adasuve PDUFA Goal Date by Three Months|
|Nov 6, 2011||Alexza Announces the Adasuve (Staccato Loxapine) PDAC Meeting Date of December 12, 2011|
|Aug 19, 2011||Alexza Announces Adasuve Staccato (Loxapine) PDUFA Goal Date of February 4, 2012|
|Aug 5, 2011||Alexza Announces Resubmission of AZ-004 (Staccato Loxapine) NDA|
|Jan 18, 2011||Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato Loxapine) NDA|
|Dec 7, 2010||Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato Loxapine)|
|Oct 11, 2010||Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato Loxapine) NDA|
|Feb 18, 2010||Alexza Announces AZ-004 (Staccato Loxapine) PDUFA Goal Date of October 11, 2010|
|Feb 10, 2010||Biovail Enters into License and Collaboration Agreement with Alexza for AZ-004|
|Dec 15, 2009||Alexza Announces Submission of AZ-004 (Staccato Loxapine) NDA|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.